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Abstract
The BinaxNOW Streptococcus pneumoniae urinary antigen test is a rapid and reliable immunochromatographic test (ICT) for the identiﬁ-
cation of a pneumococcal aetiology of pneumonia. The aim of this study was to evaluate the attitude of clinicians in their everyday prac-
tice towards prescription of the ICT and the impact of its results on the adaptation of the antibiotic therapy when pneumonia is
suspected. From October 2007 to March 2008, we prospectively evaluated 541 consecutive inpatients for whom the ICT was per-
formed in our institution. Of the 541 patients evaluated, only 233 (43%) were suspected by the treating physicians to have a pneumonia,
58 of whom had a positive ICT result. Among these 58 patients, four (7%) and 26 (45%), respectively, were treated with amoxycillin
monotherapy before and after the ICT result had been obtained (p <10)4). Although a positive ICT result led to a rise in the propor-
tion of patients treated with amoxycillin alone, a large number continued to be treated with broader-spectrum antibiotics. These results
suggest that prescription monitoring of the ICT should be implemented along with encouragement to adhere more strictly to treatment
guidelines.
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Introduction
Streptococcus pneumoniae is recognized as the most common
microorganism responsible for community-acquired pneumo-
nia [1] and, in most cases, it is still susceptible to aminopeni-
cillin. Therefore, US and French guidelines recommend,
respectively, penicillin or amoxycillin [2] and amoxycillin [3]
as the drugs of choice for pneumococcal pneumonia, as
opposed to community-acquired pneumonia without aetio-
logical identiﬁcation, for which several broad-spectrum
antibiotics, alone or in combination, are used [2]. However,
microbiological identiﬁcation of S. pneumoniae remains prob-
lematic. Blood cultures are speciﬁc but have a sensitivity of
less than 25% [4]. The sensitivities of Gram staining and cul-
ture of sputum have been estimated to be 57% and 79%,
respectively [5], but only if adequate specimens (more than
ten white blood cells per epithelial cell at a magniﬁcation of
·400) are included in the analysis. As not all patients can
produce an adequate specimen, the overall sensitivity is, in
fact, much lower, i.e. <10% [6]. Furthermore, the results of
blood and sputum culture are not available before 24–48 h,
and can become rapidly negative after antibiotic treatment,
thereby limiting their usefulness.
In contrast to these microbiological methods, cell wall
polysaccharide antigen detection in fresh, urines can lead to
a result in 15 min.
The BinaxNOW S. pneumoniae urinary antigen test (Binax
Inc., Portland, ME, USA) is a commercially available immuno-
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chromatographic test (ICT) that has a sensitivity of approxi-
mately 65% [7–9] and a speciﬁcity of more than 90% in cases
of pneumonia [8–10]. This test may remain positive for
several months after an infectious episode [11,12]. The main
interest of the ICT in cases of positivity is to allow the rapid
adaptation of the antibiotic regimen, so that aminopenicillin
rather than broader-spectrum antibiotics is used. This kind
of antibiotic switch is beneﬁcial, as amoxycillin may have a
less detrimental effect on microbial ecology than broader-
spectrum antibiotics [13], and is also less expensive. Thus,
the ICT appears to be a useful tool for the establishment of
an aetiological diagnosis of pneumonia and for the rapid
adaptation of antibiotic therapy.
The objectives of this study were, ﬁrst, to describe clinical
signs that prompt clinicians to prescribe the ICT, and sec-
ond, to evaluate the effect of a positive ICT result on anti-
biotic adaptation, an issue that has not been previously
evaluated.
Materials and Methods
Patients and setting
From October 2007 to March 2008, we conducted an obser-
vational prospective study on all inpatients of the Hopital Eu-
rope´en Georges Pompidou, a French 800-bed university
hospital of the Assistance Publique—Hoˆpitaux de Paris. All
inpatients with a presumed diagnosis of pneumonia for
whom an ICT was performed during the study period were
included. The ICT was performed whenever the attending
physician thought that it was necessary. Patients were
excluded in the case of discharge from the hospital before
the result of the ICT was available to the treating physician.
If, for a patient, the ICT was repeated several times for the
same episode of illness, only the result of the ﬁrst test was
taken into account. Patients could be included multiple times
in cases of different illnesses only if the previous ICT results
were negative. Any subsequent positive ICT result was
excluded. The distinction between different episodes of ill-
ness was based on the appreciation of the treating physician.
Antigen tests
Fresh, unconcentrated urines were tested using the Binax-
NOW S. pneumoniae urinary antigen test, which was per-
formed and interpreted according to the manufacturer’s
instructions.
Data collection
When an ICT was interpreted, we recorded which medical
department prescribed the test and then reviewed the medi-
cal chart of the patient, irrespective of the ICT result. Data
were collected concerning the medical history, the clinical
course of the disease and the results of clinical, biological
and radiological examinations. The treating physician was
interviewed for the ﬁrst time before receipt of the ICT
result and asked to give his (her) diagnosis according to one
of the following categories: pneumonia, other respiratory
tract infection, other pulmonary disease, other infectious dis-
ease, cardiac disease and other disease. The physician did
not have to justify the reason for this choice. Antibiotic regi-
mens were also recorded. We gave no advice as to antibiotic
use, although local recommendations for the management of
pneumonia were available in electronic form. During the sec-
ond interview, after receipt of the ICT result, every change
in the antibiotic regimen was recorded. As the epidemiologi-
cal data of the National Reference Laboratory showed that
the MICs for 99% of S. pneumoniae isolates were <2 mg/L in
France at the time when the study was undertaken (http://
www.invs.sante.fr/surveillance), an antibiotic switch was con-
sidered to be appropriate if monotherapy with parenteral or
oral amoxycillin was used, except in cases of allergy, where
alternative treatments included cefotaxime (in cases of non-
type 1 allergy) or levoﬂoxacin.
Statistical analysis
Continuous variables are presented as median (range), and
categorical variables as N (%). Fisher’s exact test was used to
compare categorical variables. All tests were two-sided at
the 0.05 signiﬁcance level. We analysed the impact of the
ICT results on the antibiotic regimen in the group of patients
diagnosed with pneumonia by their treating physician. Statis-
tical analyses were performed with the R 2.4.0 statistical
package (R Development Core Team; R Foundation for
Statistical Computing, Vienna, Austria (http://www.R-
project.org)).
Results
Indications for ICT prescription
Seven hundred and two ICTs were performed during the
study period (Fig. 1). Of these, 103 were not included,
because they were performed for outpatients, and 57 were
excluded because they were repeat ICTs during a single epi-
sode of illness in the same patient. One ICT was excluded
because the patient had had a previous positive ICT. There-
fore, 541 patients were evaluated. Pneumonia was diagnosed
in 233 patients (‘pneumonia’ group) (Table 1). Three hun-
dred and eight patients had other diagnoses: 79 were ‘other
respiratory infections’, 83 ‘other infectious diseases’, 47
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‘non-infectious pulmonary diseases’, 44 ‘cardiac deﬁciencies’
and 55 ‘other diseases’; they were not included in the
analysis.
ICT results
In the group of patients with pneumonia, 58 of 233 ICT
results (25%) were positive (Fig. 1). Among the 58 patients
with positive ICT results, 17 patients had both a positive
ICT result and S. pneumoniae present in a clinically relevant
microbiological sample (cultures were negative in 35 cases
and not performed in six).
Adaptation of antibiotherapy in the pneumonia group
We reviewed how treating physicians adapted antibiotic regi-
mens after receiving the ICT results in the group of patients
diagnosed with pneumonia (N = 233). Before receipt of the
ICT results (Table 2), amoxycillin–clavulanic acid alone was
the most frequently prescribed antibiotic (81 patients, 35%),
followed by combinations of a macrolide or a ﬂuoroquino-
lone with a b-lactam (54 patients, 23%). Cefotaxime or
amoxycillin alone were less frequently used.
Twenty-eight patients (12%) did not receive any antibiot-
ics. After communication of the ICT results, antibiotic pre-
scription was similar, except that the proportion of patients
treated with amoxycillin rose from 5% to 15% (p < 0.001).
The proportion of non-treated patients decreased to 3%
(p < 0.001) (Table 2).
As a positive ICT result should contribute to the adapta-
tion of antibiotic prescription, we further analysed the
changes in the antibiotic regimen in the subgroup of patients
with a positive ICT result (Table 2). Before knowledge of
the ICT results, patients were mostly treated with amoxycil-
lin–clavulanic acid, a combination therapy or cefotaxime.
Four patients received amoxycillin, and nine were not
ICT performed over the study period 
n = 702 
Outpatients
n = 103 
Repeated ICT 
n = 57 
Previous positive ICT
n = 1 
ICT included in the analyses 
n = 541 
Pneumonia 
n = 233 
ICT results: 
58 Positive (25%) 
175 Negative (75%)
Other diagnoses 
n = 308 
ICT results: 
18 Positive (6%) 
290 Negative (94%)
FIG. 1. Flow chart of the study, showing the number of patients
included and results of the immunochromatographic test (ICT).
Numbers refer to the numbers of patients.
TABLE 1. Clinical and paraclinical features of the 233
patients studied (percentage of total in parentheses unless
otherwise stated)
Patient characteristics
Pneumonia group
N = 233
Comorbidities
Cardiac insufﬁciency 34 (15)
Chronic respiratory disease 44 (19)
Diabetes 21 (9)
Immunosuppression 43 (18)
History of neoplasia 50 (21)
Clinical ﬁndings
Chills 49 (21)
Cough 160 (69)
Fever 164 (70)
Expectoration 108 (46)
Dyspnoea 145 (62)
Desaturation 146 (63)
Crackles 156 (67)
Paraclinical ﬁndings
WBC count (mean ± SD) 13 300 ± 11 520
Abnormal chest X-ray 218 (94)
Alveolar condensation 197 (85)
Interstitial inﬁltrate 9 (4)
Pleural effusion 10 (4)
Other radiological image 12 (5)
Chest X-ray not performed 0 (0)
Blood culture drawn 184 (79)
Positive blood culturea 5 (2)
Respiratory sample 144 (62)
Positive respiratory samplea 26 (18)
SD, standard deviation; WBC, white blood cell.
aPositive blood cultures and positive respiratory samples refer to the number of
cultures positive for Streptococcus pneumoniae only.
TABLE 2: Antibiotic regimen before and after the results of
the immunochromatographic test (ICT), in the group of
patients diagnosed with pneumonia (n = 233, percentage in
parentheses)
Antibiotic regimen
Number of patients
paBefore ICT result After ICT results
All patients (N = 233)
AMC 81 (35) 82 (35) 1
Combinedb 54 (23) 43 (18) 0.25
Cefotaxime 31 (13) 36(15) 0.60
Amoxycillin 11 (5) 35 (15) <0.001
Otherc 28 (12) 29(12) 1
No antibiotic 28 (12) 8 (3) <0.001
Patients with positive ICT result (N = 58)
AMC 19 (33) 9 (16) 0.05
Combinedb 13 (22) 3 (5) 0.01
Cefotaxime 9 (16) 16 (28) 0.17
Amoxycillin 4 (7) 26 (45) <0.0001
Otherc 4 (7) 4 (7) 1
No antibiotic 9 (16) 0 (0) 0.003
AMC, amoxycillin–clavulanic acid.
ap-values calculated using Fisher’s exact tests.
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treated with antibiotics. After receipt of the ICT results, all
patients were treated with antibiotics. Twenty-six received
amoxycillin and 16 received cefotaxime (Table 2). In both
cases, the increase in the number of patients treated with
amoxycillin after a positive ICT result was statistically signiﬁ-
cant, as was the decrease in the number of patients treated
with amoxycillin–clavulanic acid or combined therapy.
In summary, 233 patients were diagnosed with pneumonia.
In this group (Table 3), after knowledge of the ICT result, the
antibiotic regimen was not changed for 161 patients, the regi-
men was adapted in 22 of 58 cases and changed to amoxycillin
after a positive ICT result, and six of 175 patients were trea-
ted with broader-range regimens after a negative ICT result.
Discussion
The impact of the ICT result on the aetiological diagnosis of
pneumonia is well documented [14]. The sensitivity and
speciﬁcity of the test are sufﬁcient to allow a conﬁdent
switch from a broad-spectrum to a more speciﬁc antibiotic
regimen against S. pneumoniae [7,10]. Although urinary anti-
gen detection has been found to be useless for the diagnosis
of pneumonia [10], it is true that this test is often misused
for this purpose in clinical practice.
Distinguishing pneumonia from other pneumological afﬂic-
tions is sometimes challenging, especially in elderly patients.
In the absence of a unique diagnostic reference criterion, phy-
sicians tend to rely on a number of criteria to establish the
diagnosis [15]. We deliberately chose to use the clinician’s
diagnosis as the standard for the identiﬁcation of patients
with pneumonia, rather than an independent review, as we
were attempting to analyse physicians’ behaviour. In our
study, more than half of the ICTs were performed for
patients who were not considered, by the prescriber, to have
pneumonia. This ﬁnding can be explained by the fact that
some physicians probably use the ICT as a means to diagnose
pneumonia rather than the aetiology of the pneumonia.
Another striking element is the relatively high rate of multi-
ple ICTs prescribed for the same patient (8%) (data not
shown). One explanation is the presence of multiple care-tak-
ers (interns, fellows and seniors), who might prescribe it
repeatedly. Another explanation is that the patient often does
not stay in the emergency department but is transferred to a
general ward; it can then sometimes be difﬁcult to view the
computerized prescription made at the emergency depart-
ment. A third explanation is that the physician wants to
repeat the ICT in order to increase the sensitivity, although
this possibility has not been demonstrated. This excess of
ICT prescriptions comes with an economic cost. One ICT kit
costs €20 and an additional €7 of labour costs. In our hospital,
more than 1300 ICTs are performed each year. Taking dupli-
cate and unnecessary ICTs into account (8% and 57%, respec-
tively), we estimated a surplus cost of€22 000 per year.
The ICT allowed the aetiological diagnosis in an additional
17% of the patients who had pneumonia with no S. pneumo-
niae-positive cultures. This number is comparable to that
obtained in other studies [14,16].
There are differences in the adherence to guidelines as
reported in published studies [17–19]. In the pneumonia
group of this study, although a positive ICT result led to a
greater proportion of patients being treated with amoxycillin
(45% vs. 7%, p <0.01), there was still fairly poor adherence
to the national guidelines for the management of pneumonia,
which advocate the use of amoxycillin in pneumococcal
pneumonia [2,3].
Overall, the impact of an ICT on changing the antibiotic
regimen appeared to be low in this study (Table 3), because
a positive ICT result did not lead to the use of a narrow-
spectrum antibiotic such as amoxycillin. Other reports have
found that blood culture results have a limited impact on
changing the antibiotic regimen in cases of pneumonia, even
when they are positive [20,21]. These ﬁndings raise the ques-
tion of the usefulness of microbiological examinations in
non-severe pneumonia [2], as there is limited impact on the
adaptation of therapy. This can be explained by the reluc-
tance of physicians to prescribe narrow-spectrum antibiotics
and to change a ‘winning team’ [22]. However, this habit
could lead to the alteration of the human bacterial ﬂora and
the selection of resistant microorganisms.
This study has several limitations. First, it was conducted
in one single centre, and generalization could therefore be
TABLE 3. Impact of immunochromatographic test (ICT)
results on the antibiotic regimen in the pneumonia group
(n = 233, percentage in parentheses)
Impact on the antibiotic regimen Number (%) of patients
ICT positive (N = 58)
Change adapteda 22 (9)
Change not adapted 14 (6)
No change 20 (9)
ICT negative (N = 175)b
Initiation of therapy 11 (5)
Step-downc 8 (3)
Broader-range therapyd 6 (3)
Other change 9 (4)
No change 141 (61)
aIn cases of positive ICT results, a change was considered to be adapted if anti-
biotic therapy was switched to amoxycillin or, in cases of allergy, to cefotaxime
or levoﬂoxacin (see Materials and Methods).
bIn cases of negative ICT results, a BinaxNOW urinary Legionella test was per-
formed immediately, which could explain some step-downs.
cSwitching from a combination regimen to a monotherapy.
dAdding a quinolone or a macrolide to the antibiotic regimen.
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problematic, as prescription habits could be different else-
where. Second, during the study, we established direct con-
tact with the physicians in charge of the patients soon after
receipt of the ICT result. Therefore, even in the absence of
any therapeutic advice, an inﬂuence on antibiotic prescription
practices was possible, and the effect of the ICT in clinical
practice could actually be much lower. Another potential
limitation was that the majority of the patients were from
the emergency department, and diagnosing pneumonia could
be a way of justifying hospitalization or antibiotic use. How-
ever, we did not ﬁnd any difference in the percentages of
pneumonia patients between the emergency department
(118 of 308, 38%) and overall (77 of 203, 38%).
Finally, we did not evaluate the clinical impact of any anti-
biotic regimen modiﬁcation in terms of mortality, morbidity
or length of hospital stay. Therefore, no conclusions can be
drawn concerning the safety of the adaptation of the antibi-
otic regimen and the true clinical implications of a positive
ICT result.
In summary, although the ICT has a good sensitivity and
speciﬁcity, it is misused in our institution, with more than
50% of the tests being performed in patients without pneu-
monia. Although a positive ICT result led to a rise in the
proportion of patients treated with amoxycillin and a
decrease in the proportion of patients treated with combina-
tion therapy, insufﬁcient adherence to treatment guidelines
for pneumonia when an ICT result is positive contributes to
limiting its impact. For this reason, we recommend that pre-
scription monitoring of the ICT should be implemented,
along with encouragement to adhere more strictly to treat-
ment guidelines.
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